Sim&Cure is a medical technology company that pioneers, amongst other products, a patient-based computational model for aneurysm treatment called Sim&Size™. Sim&Size™ provides personalized and clinically accurate computational modeling to facilitate the selection and placement of medical devices (Flow Diverter, Intrasaccular Device, Laser-cut Stent, First Coil).
With over 5000 successful cases in over 400 hospitals across the globe, Sim&Size™ delivers value by being highly efficient.
The Journey So Far
2013
Project IRRAS-TECHNOLOGY begins incubation in LRI (Languedoc Rousillon Incubation)
2014
Creation of Sim&Cure by PhD Mathieu Sanchez and Prof. Vincent Costalat
2015
IT Translation seed round
2016
IDsize and FDsize module.
100+ simulations in European Hospitals.
Innovation Awards “COSTI Favorite”.
Participation to four international events and presentations; ABC WIN, LINNC Paris, ESMINT, SNIS.
Move into bigger office.
2017
Sim&Size™ and its module IDsize, FDsize received the CE mark approval.
200+ simulations in European hospitals.
3 international clients; world’s biggest medical devices companies.
9 employees, 2 interns.
2018
Sim&Size™ commercial Launch
Sim&Size™ STsize module launch
1500+ Patient treated
+2 employees
6 international congresses
2019
Series A financing with Elaia and IT Translation Investment
Opening US subsidiary: Sim & Cure Inc
Obtained US Food and Drug Administration (FDA) 510 (k) clearance on September 17, 2019.
Sim&Size™ FCsize module launch
2020
New headquarter in Montpellier, France.
500+ patients in USA treated with Sim&Size™
2000 patients treated with Sim&Size™
10+ recruitments
3 Sim&Size™ releases
Online conferences